Menopause & midlife

The WHI Study: What 2002 Got Wrong About HRT

Save

HRT use fell by about half in 2002 after the Women's Health Initiative reported higher breast cancer and heart risk. Later reanalysis showed the trial studied mostly older women, averaging age 63 and a decade past menopause, using one formulation. For healthy women under 60, benefits generally outweigh the small absolute risks.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why did HRT use drop so sharply after 2002?

In July 2002, the first results of the Women's Health Initiative (WHI) reached the news, and prescriptions for menopausal hormone therapy fell by roughly 50% within 12 months 1. The trial reported that combined estrogen-plus-progestin therapy raised breast cancer, heart disease, stroke, and clot risk, and its monitoring board halted that arm about 3 years early 1. Headlines compressed a nuanced finding into a single message: hormones are dangerous.

Millions of women stopped their hormones abruptly, and a generation of clinicians grew wary of prescribing at all. According to the North American Menopause Society, that reaction outran what the data justified for younger women near menopause 2. The episode became a cautionary tale about how one trial, read without nuance, can reshape practice for 20 years.

What did the WHI actually study?

The WHI enrolled more than 16,000 women in its combined-therapy arm, but they were not typical of women seeking symptom relief 1. Participants averaged about 63 years of age, and many were more than 10 years past their final period, a stage when arteries and breast tissue respond differently to hormones 1. The study tested a single formulation: oral conjugated equine estrogen paired with medroxyprogesterone acetate, swallowed as a daily pill 1.

The trial was designed to ask whether hormones could prevent chronic disease in later life, not whether they safely relieve hot flashes in a woman of 52. According to the study's own authors, those design choices shaped every headline that followed 1. Applying it to a 50-year-old with night sweats stretches the evidence.

How did later reanalyses change the picture?

Reanalysis by age transformed how experts read the WHI. When investigators separated participants by age, women who began therapy in their 50s or within 10 years of menopause showed a more favorable balance than the older group driving the alarming averages 3. The estrogen-alone arm, in women who had had a hysterectomy, told a different story: it did not raise breast cancer risk, and across 18 years of follow-up neither regimen increased all-cause mortality 45.

Because the trial studied women who were on average a decade or more past menopause, its findings map poorly onto someone weighing therapy during the perimenopausal transition 32. In short, when therapy starts matters as much as whether it is used. This 'timing hypothesis' now anchors the 2022 society position statement 2.

What do the absolute numbers show?

Absolute risk tells a calmer story than relative risk. In the combined-therapy arm, for every 10,000 women treated for one year, the WHI counted roughly 8 extra breast cancers, 7 more coronary events, 8 more strokes, and 8 more blood clots, while fractures fell 1. Framed per person, that is fewer than 1 in 100 women a year.

Set against a woman's everyday risks, an increase of a few cases per 10,000 is modest, though not zero. Long-term follow-up published in 2020 found combined therapy raised breast cancer incidence modestly, whereas estrogen alone slightly lowered it 6. For a healthy woman under 60, the North American Menopause Society concludes the benefits generally outweigh these small risks, and the breast cancer numbers deserve a closer look 2.

When WHI worries need a menopause specialist

A clinician who focuses on menopause can place the WHI in the context of your own history rather than the 2002 headlines. Your age, years since your final period, symptom severity, and personal or family history of breast cancer or blood clots all shift the balance in ways a single study cannot capture.

A gynecologist, menopause specialist, or informed primary care clinician can walk through current guidance, compare formulations and routes, and revisit the plan over time. Gale can help you prepare for that conversation. The 2002 scare was real, but two decades of follow-up have reframed what it means for women today.

Common questions

For most healthy women under 60 or within 10 years of menopause, current guidance finds the benefits generally outweigh the small absolute risks. The 2002 alarm came from a trial of older women using one formulation, and the picture looks different for women closer to the menopause transition.

The monitoring board halted the combined estrogen-plus-progestin arm when it crossed a preset threshold for breast cancer and cardiovascular events. The estrogen-alone arm was later stopped for a stroke signal. Stopping early was a safety step, not proof that hormones harm every woman.

Partly. Its findings remain relevant for women who start hormones well after 60 or many years past menopause, where risks run higher. For a woman in her early fifties with hot flashes, the age-stratified reanalysis is a better guide.

Not entirely. The WHI tested oral conjugated equine estrogen with medroxyprogesterone acetate. Many women today use transdermal estradiol and micronized progesterone, which have different clot and metabolic profiles, though long-term trial data on newer forms remain limited.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to revisit hormone therapy with a clinician

  • —A new breast lump, skin dimpling, or nipple change while on hormone therapy is a reason to seek prompt clinician review.
  • —Unexplained vaginal bleeding after starting hormone therapy is a reason to arrange a gynecologic evaluation.
  • —Sudden shortness of breath, chest pain, or one-sided leg swelling can signal a blood clot and is a reason to seek emergency care.
  • —Sudden severe headache, face or limb weakness, or slurred speech can signal a stroke and is a reason to call for emergency help.

Sudden shortness of breath, chest pain, one-sided leg swelling, or signs of a stroke such as face or limb weakness can signal a blood clot or stroke — call 911 or go to the nearest emergency room right away.

This article is general health education, not medical advice. Whether hormone therapy fits your history is a decision to make with a gynecologist, menopause specialist, or primary care clinician who knows your full picture.

References

  1. 1.Rossouw JE, Anderson GL, Prentice RL, et al. / Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. doi:10.1001/jama.288.3.321 ✓The 2002 WHI estrogen-plus-progestin trial: enrollment averaging age 63, a single oral formulation, early stopping, and the per-10,000 absolute event counts that drove the 2002 alarm.
  2. 2.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓Current consensus that for healthy women under 60 or within 10 years of menopause the benefits of hormone therapy generally outweigh risks, reframing the WHI via the timing hypothesis.
  3. 3.Manson JE, Chlebowski RT, Stefanick ML, et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. doi:10.1001/jama.2013.278040 ✓Age-stratified WHI reanalysis showing a more favorable balance for women who began therapy in their 50s or within 10 years of menopause.
  4. 4.Anderson GL, Limacher M, Assaf AR, et al. / Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. doi:10.1001/jama.291.14.1701 ✓The WHI estrogen-alone (hysterectomy) arm, which did not raise breast cancer risk.
  5. 5.Manson JE, Aragaki AK, Rossouw JE, et al. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. doi:10.1001/jama.2017.11217 ✓Eighteen-year WHI follow-up finding neither regimen increased all-cause mortality.
  6. 6.Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. doi:10.1001/jama.2020.9482 ✓Long-term WHI follow-up showing combined therapy modestly raised breast cancer incidence while estrogen alone slightly lowered it.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library